Differences in the inflammatory response among hospitalized patients with distinct variants of SARS-CoV-2.
COVID-19 variants
SARS-CoV2 (COVID- 19)
Spain
alpha
delta
inflammation
omicron
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
27
07
2023
accepted:
25
09
2023
medline:
2
11
2023
pubmed:
1
11
2023
entrez:
1
11
2023
Statut:
epublish
Résumé
The SARS-CoV-2 variants demonstrate diverse transmission patterns, modifications in infectivity, and immune response. Changes in disease manifestation may be attributed to vaccination and the virus's reduced capacity to induce inflammation. To investigate the relationship between the inflammatory response and the characteristics of COVID-19 across successive waves. A retrospective cross-sectional study was conducted to evaluate sociodemographic, clinical, and laboratory data of Alpha (G1), Delta (G2), and Omicron (G3) variants. A total of 300 patients from a hospital in Madrid, Spain, were included. The groups exhibited similar sociodemographic and baseline characteristics. The Alpha variant predominantly affected younger patients, while the Omicron variant affected patients with a higher prevalence of comorbidities. The Alpha group had the lowest vaccination rate compared to the highest rate in the Omicron group. The Alpha group received a higher proportion of tocilizumab compared to the other groups. Despite these differences, the severity scores were similar among the three variants. Regarding laboratory parameters, differences were observed in haemoglobin, D-dimer, alkaline phosphatase, and potassium levels. The Omicron variant showed higher D-dimer levels (p=0.04). In the multivariate analysis, differences in leukocyte count, haemoglobin, alkaline phosphatase, and potassium levels were consistently observed among patients from different waves. Omicron exhibited a higher absolute leukocyte count than the Alpha variant (p=0.003). No significant differences were found in inflammation biomarkers among the three variants. Furthermore, there were no significant disparities in mortality or disease severity. The level of inflammatory response in patients may be determined by the severity of COVID-19, rather than the specific viral variant.
Identifiants
pubmed: 37908351
doi: 10.3389/fimmu.2023.1267991
pmc: PMC10613978
doi:
Substances chimiques
Alkaline Phosphatase
EC 3.1.3.1
Coloring Agents
0
Hemoglobins
0
Potassium
RWP5GA015D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1267991Informations de copyright
Copyright © 2023 Homen-Fernandez, Valls, García, Cabello, Ortega, Orviz, Foncubierta, Martínez and Estrada.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Immunol. 2022 Apr 27;13:857573
pubmed: 35572561
Science. 2021 Aug 6;373(6555):
pubmed: 34168071
J Med Virol. 2022 Apr;94(4):1738-1744
pubmed: 34905235
MedComm (2020). 2021 Dec 16;2(4):838-845
pubmed: 34957469
Emerg Microbes Infect. 2022 Dec;11(1):1-5
pubmed: 34890524
Euro Surveill. 2021 Jan;26(1):
pubmed: 33413740
Open Respir Arch. 2022 Feb 24;4(2):100169
pubmed: 37497318
Nat Rev Microbiol. 2023 Mar;21(3):162-177
pubmed: 36653446
Lancet. 2021 Apr 10;397(10282):1351-1362
pubmed: 33798499
Front Immunol. 2021 Nov 30;12:751778
pubmed: 34917076
Euro Surveill. 2021 Jan;26(3):
pubmed: 33478625
Int J Mol Sci. 2021 Jul 10;22(14):
pubmed: 34299045
Cell. 2022 Feb 3;185(3):467-484.e15
pubmed: 35081335
Proc Natl Acad Sci U S A. 2022 May 24;119(21):e2200413119
pubmed: 35576468
Nat Aging. 2021 Sep;1(9):769-782
pubmed: 34746804
Cell Host Microbe. 2021 Apr 14;29(4):529-539.e3
pubmed: 33705729